Baiyang Pharmaceutical and Peking University Third Hospital jointly establish a research and development center to address pioneering innovations in reproductive health.

Beijing News (Reporter Zhang Zhaohui) — On March 18, Peking University Third Hospital (referred to as “PKU Third Hospital”) and Boyang Pharmaceutical Group’s innovation incubation platform, Boyang Chengchuang, reached a strategic partnership to jointly establish the “PKU Third Hospital-Boyang Chengchuang Reproductive Function Repair Joint R&D Center,” promoting the research and technological transformation of innovative drugs for reproductive endocrine disease treatment.

Ovaries and the uterus are core organs of the female reproductive system. Their functional issues not only affect fertility but also relate to women’s health and quality of life throughout their lifespan. Studies show that reproductive endocrine abnormalities such as ovarian decline and endometrial damage are closely linked to the development of chronic diseases like cardiovascular disease and osteoporosis. Age-related physiological ovarian fibrosis is a key factor in natural ovarian decline, and the repair process after endometrial damage also involves fibrosis. Therefore, anti-fibrosis repair becomes a critical breakthrough in restoring reproductive function.

The establishment of the “PKU Third Hospital-Boyang Chengchuang Reproductive Function Repair Joint R&D Center” directly addresses this clinical pain point and aligns with Boyang’s long-term strategy in the field of organ fibrosis. The center will be led by Professor Li Rong, Vice President of PKU Third Hospital and Director of the Reproductive Medicine Center, focusing on research areas such as ovarian function improvement and endometrial repair to promote female fertility. The center will develop and translate new drugs, products, and technologies, while also advancing professional talent training and domestic and international academic exchanges.

Jin Changxiao, Secretary of the Party Committee of PKU Third Hospital, expressed hope that through the cooperation of the joint R&D center and leveraging Boyang’s comprehensive innovation incubation and industry empowerment system, the source innovations from clinical discoveries and basic research can be accelerated into new drugs and technologies accessible to patients. This will support the improvement of women’s health throughout their lifespan in China and serve national strategic needs.

Qiao Jie, Vice Chairman of the China Association for Science and Technology, Academician of the Chinese Academy of Engineering, and Director of Peking University Health Science Center, pointed out that technological innovation should be collaborative from the source. He hopes that this cooperation, relying on the joint R&D center, will attract multidisciplinary talents, cultivate high-level research teams, and achieve dual breakthroughs in drug and medical device innovation and talent development, setting an example of industry-academia collaborative innovation in reproductive health.